Dual L- and N-type calcium channel blocker that displays antihypertensive, sympatholytic and neuroprotective activity. Lowers mean blood pressure and reduces the size of cerebral infarction in the rat model of focal brain ischemia.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 492.52. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.03 mL||10.15 mL||20.3 mL|
|5 mM||0.41 mL||2.03 mL||4.06 mL|
|10 mM||0.2 mL||1.02 mL||2.03 mL|
|50 mM||0.04 mL||0.2 mL||0.41 mL|
References are publications that support the products' biological activity.
Murai et al (2000) Preferential inhibition of L- and N-type calcium channels in the rat hippocampal neurons by cilnidipine. Brain Res. 854 6 PMID: 10784100
Takahara et al (2004) Neuroprotective effects of a dual L/N-type Ca2+ channel blocker cilnidipine in the rat focal brain ischemia model. Biol.Pharm.Bull. 27 1388 PMID: 15340224
If you know of a relevant reference for Cilnidipine, please let us know.
View Related Products by Product Action
Keywords: Cilnidipine, supplier, Ca2+, channel, blockers, dual, L/N-type, Calcium, CaV, Channels, L-Type, N-Type, voltage-gated, voltage-dependent, FRC8653, FRC, 8653, Voltage-gated, Calcium, Channels, Voltage-gated, Calcium, Channels, Tocris Bioscience
Citations for Cilnidipine
Citations are publications that use Tocris products.
Currently there are no citations for Cilnidipine. Do you know of a great paper that uses Cilnidipine from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.